Picton Mahoney Asset Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-63
Closed -$4K 1035
2025
Q1
$4K Buy
+63
New +$4.51K ﹤0.01% 654
2022
Q4
Sell
-71,663
Closed -$5.92M 697
2022
Q3
$5.92M Buy
71,663
+38,800
+118% +$3.73M 0.21% 93
2022
Q2
$3.13M Buy
32,863
+40
+0.1% +$4.14K 0.12% 234
2022
Q1
$3.87M Sell
32,823
-1,477
-4% -$166K 0.14% 201
2021
Q4
$4.44M Buy
+34,300
New +$4M 0.11% 154
2021
Q1
Sell
-151,541
Closed -$13.8M 351
2020
Q4
$13.8M Sell
151,541
-2,114
-1% -$175K 0.66% 38
2020
Q3
$12.3M Sell
153,655
-14,185
-8% -$1.11M 0.68% 42
2020
Q2
$11.6M Buy
+167,840
New +$11.9M 0.67% 49
2017
Q3
Sell
-743,241
Closed -$28.3M 197
2017
Q2
$29.3M Sell
743,241
-170,400
-19% -$6.22M 2.09% 4
2017
Q1
$28.6M Buy
913,641
+6,450
+0.7% +$202K 1.92% 4
2016
Q4
$28.3M Sell
907,191
-381,159
-30% -$12.3M 2.33% 2
2016
Q3
$51.8M Buy
1,288,350
+41,400
+3% +$1.56M 3.47% 1
2016
Q2
$41.5M Sell
1,246,950
-57,900
-4% -$1.98M 2.55% 3
2016
Q1
$38.4M Buy
1,304,850
+735,150
+129% +$20.3M 2.46% 2
2015
Q4
$15M Buy
+569,700
New +$14.8M 0.9% 35

Other funds holding EW

Picton Mahoney Asset Management's EW Position: Q2 2025 in Review

Picton Mahoney Asset Management sold out of Edwards Lifesciences (EW) in Q2 2025, closing a stake of 63 shares — an estimated $4K sold.

Picton Mahoney Asset Management first reported a position in EW in Q4 2015 and held it in 15 quarters. The position peaked at $51.8M in Q3 2016. 1,260 funds tracked by Wall St. Rank hold EW as of Q2 2025.

  • Picton Mahoney Asset Management reported no remaining Edwards Lifesciences position as of Q2 2025 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 63 Edwards Lifesciences shares in Q2 2025, an estimated $4K.
  • Picton Mahoney Asset Management first reported a position in Edwards Lifesciences in Q4 2015 and held it in 15 quarters.
  • Picton Mahoney Asset Management's Edwards Lifesciences position peaked at $51.8M in Q3 2016.
  • 1,260 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2025.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.